| Literature DB >> 35421790 |
Wael M Elshemey1, Abdo A Elfiky2, Ibrahim M Ibrahim2, Alaa M Elgohary2.
Abstract
Finding a potent inhibitor to the pandemic SARS-CoV-2 is indispensable nowadays. Currently, in-silico methods work as expeditious investigators to screen drugs for possible repurposing or design new ones. Targeting one of the possible SARS-CoV-2 attachment and entry receptors, Glucose-regulated protein 78 (GRP78), is an approach of major interest. Recently, GRP78 was reported as a recognized representative in recognition of the latest variants of SARS-CoV-2. In this work, molecular docking and molecular dynamics simulations were performed on the host cell receptor GRP78. With its many terpenoid compounds, Chaga mushroom was tested as a potential therapeutic against the SARS-CoV-2 receptor, GRP78. Results revealed low binding energies (high affinities) toward the GRP78 substrate-binding domain β (SBDβ) of Chaga mushroom terpenoids. Even the highly specific cyclic peptide Pep42, which selectively targeted GRP78 over cancer cells in vivo, showed lower binding affinity against GRP78 SBDβ compared to the binding affinities of terpenoids. These are auspicious results that need to be tested experimentally. Intriguingly, terpenoids work as a double sword as they can be used to interfere with VUI 202,012/01, 501.V2, and B.1.1.248 variants of SARS-CoV-2 spike recognition.Entities:
Keywords: COVID-19; Chaga terpenoids; GRP78; HSPA5; MM-GBSA; NAMD
Mesh:
Substances:
Year: 2022 PMID: 35421790 PMCID: PMC8988443 DOI: 10.1016/j.compbiomed.2022.105478
Source DB: PubMed Journal: Comput Biol Med ISSN: 0010-4825 Impact factor: 6.698
Fig. 12D structures of the terpenoids ranked according to their binding affinities to GRP78 RBDβ.
Fig. 2The average binding energy (in kcal/mol) was calculated using AutoDock Vina software for docking the 28 terpenoid compounds against the four different conformations of GRP78 SBDβ. The peptide Pep42 and EGCG (red columns) are positive controls due to their specificity in binding HSPA5. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
The interactions were established on selected ligand-GRP78 complexes based on binding affinity values. Bold residues are the most repeated interactions in most ligands.
| H-bonding | Hydrophobic interaction | π-interaction | ||||
|---|---|---|---|---|---|---|
| Ligand | Number | Amino acids involved from GRP78 | Number | Amino acids involved from GRP78 | Number | Amino acids involved from GRP78 |
| Pep42 | 3 | Q449(2), Q492 | 2 | I450 and V453 | 2 | I426 and F451 |
| EGCG | 1 | E427 | 5 | I426, F451, I459(2), and K460 | 1 | F451 |
| 6 | I426(2), | 1 | F451 | |||
| 1 | I450 | 7 | ||||
| 1 | E427 | 7 | 1 | F451 | ||
| 7 | 1 | F451 | ||||
| 5 | ||||||
| 1 | T458 | 4 | 3 | V429, F451(2) | ||
| 6 | ||||||
| 4 | 1 | F451 | ||||
| 7 | I426(2), | 1 | F451 | |||
| 9 | I426(2), | 1 | F451 | |||
| 12 | I426, | |||||
| 11 | 1 | F451 | ||||
| 9 | I426, | |||||
| 1 | E427 | 8 | I426, | 1 | F451 | |
| 2 | I450 and K460 | 7 | I426 (2), | |||
| 9 | ||||||
| Betulinic acid | 2 | E427 and I450 | 4 | |||
| 5 | ||||||
| 11 | ||||||
| 7 | I426, | |||||
| 7 | 1 | F451 | ||||
| 2 | Q449 and T458 | 6 | 1 | F451 | ||
| 6 | ||||||
| 2 | K460(2) | 7 | 1 | F451 | ||
| 3 | E427(2) and G430 | 6 | ||||
| 2 | E427 and T428 | 7 | I426(2), | |||
| 9 | I426, | |||||
| 1 | T458 | 4 | I426, | 1 | F451 | |
Fig. 3A) The interaction pattern of Pep42 cyclic peptide (white cartoon and sticks) with GRP78 SBDβ (wires). The protein surface is calculated and represented by the hydrophobicity according to the color scheme at the figure's lower-left corner. (B) The interaction pattern of Betulinic acid and Inonotsane C (sticks) against GRP78 SBDβ (wires). The H-bonds and hydrophobic contacts are depicted by dashed-green lines and dashed-iris lines, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
The MM-GBSA calculations for the best two complexes after 50 ns MDS. Red-colored residues represent the residues that have a negative contribution to binding (positive binding energies). The average binding free energies and their terms are shown at the bottom of the table for each complex with its standard deviations.
| COMPLEX | ||||
|---|---|---|---|---|
ΔE Van Der Waal's potential energy contribution, ΔE Electrostatic potential energy contribution, ΔG Generalized Bohrn binding energy contribution, ΔG Surface Area binding energy contribution, ΔG GAS, Gas-phase binding energy contribution ΔG SOLV solvation binding energy contribution, ΔG TOTAL total binding energy.
Fig. 4(A) Root mean square deviation (RMSD) in Å and Radius of Gyration (RoG) in Å, Surface Accessible Scheme 2 and number of H-bonds versus time in ns for the MD simulation of GRP78-Oleanolic acid (orange) and GRP78-Inonotsulide A (gray) complexes. (B) Root Mean Square Fluctuations (RMSF) versus residue number of apo-GRP78 (blue), GRP78- Oleanolic acid (orange), and GRP78-Inonotsulide A (gray) complexes. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Lipinski's rule of five for the terpenoids studied in this work. Green numbers indicate that the value agrees with the rule of five. Red numbers indicate that the value is higher than the threshold.
| Compounds names | Number of H-donors | number of H-acceptors | LogP | Molecular weight |
|---|---|---|---|---|
| Inonotsutriol D | 3 | 3 | 1.58314 | 411.351 |
| Inonotsutriol B | 3 | 3 | 0.91655 | 411.351 |
| Inonotsuoxodiol A | 2 | 3 | 1.24775 | 410.343 |
| Inonotsuoxide A | 2 | 3 | 1.40515 | 410.343 |
| Inonotsulide C | 2 | 4 | 0.51276 | 426.342 |
| Inonotsulide A | 2 | 4 | 0.51276 | 426.342 |
| Inonotsudiol A | 2 | 2 | 1.75994 | 394.344 |
| Ergosterol peroxide | 1 | 3 | 1.22716 | 385.313 |
| Ergosterol | 1 | 1 | 1.93674 | 353.315 |
| Betulinic acid | 2 | 2 | 1.35196 | 410.343 |
| Betulin | 2 | 2 | 1.67865 | 394.344 |
| 3b Hydroxycinnamolide | 1 | 3 | 0.29938 | 229.17 |
| Trametenolic acid | 2 | 2 | 1.43325 | 410.343 |
| Spiroinonotsuoxodiol | 2 | 3 | 1.16646 | 410.343 |
| Oleanolic acid | 2 | 2 | 1.27067 | 410.343 |
| Lanosterol | 1 | 1 | 1.93674 | 377.337 |
| Inotodiol | 2 | 2 | 1.75994 | 394.344 |
| Inonotusol G | 2 | 3 | 6.33366 | 456.711 |
| Inonotusol F | 1 | 3 | 1.43744 | 421.346 |
| Inonotusol E | 4 | 5 | 0.22756 | 444.357 |
| Inonotusol D | 5 | 5 | 0.56295 | 445.365 |
| Inonotusol C | 5 | 5 | 0.56295 | 445.365 |
| Inonotusol B | 5 | 6 | 0.05076 | 461.364 |
| Inonotusol A | 5 | 6 | 0.05076 | 461.364 |
| Inonotusic acid | 0 | 2 | 5.0495 | 312.453 |
| Inonotusane C | 1 | 1 | 1.57407 | 357.303 |
| Inonotusane B | 3 | 3 | 0.91655 | 411.351 |
| Inonotsutriol E | 3 | 3 | 1.58314 | 411.351 |
The Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of the tested terpenoids as calculated using pkCSM webserver.
| Absorbtion | Distribution | Metabolism | Excretion | Toxicity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound name | |||||||||||||||
| Inonotsutriol D | −4.32 | 1.373 | 100 | 0.095 | −0.275 | No | No | No | No | No | No | No | No | No | No |
| Inonotsutriol B | −4.251 | 1.2 | 49.745 | 0.094 | 0.569 | No | No | No | No | No | No | No | No | No | No |
| Inonotsuoxodiol A | −4.593 | 1.384 | 59.213 | 0.118 | 0.543 | No | No | No | No | No | No | No | No | No | No |
| Inonotsuoxide A | −4.546 | 1.204 | 100 | 0.062 | 0.611 | No | No | No | No | No | No | No | No | No | No |
| Inonotsulide C | −4.456 | 0.313 | 60.549 | 0.084 | 0.464 | No | No | No | No | No | No | No | No | No | No |
| Inonotsulide A | −4.363 | 0.438 | 60.385 | 0.11 | 0.535 | No | No | No | No | No | No | No | No | No | No |
| Inonotsudiol A | −4.345 | 1.276 | 100 | 0 | −0.336 | No | No | No | No | No | No | No | No | No | No |
| Ergosterol peroxide | −3.642 | 1.251 | 80.472 | 0.139 | 0.497 | No | No | No | No | No | No | No | No | Yes | No |
| Ergosterol | −4.927 | 1.255 | 100 | 0.025 | 1.159 | No | No | No | No | No | No | No | No | Yes | No |
| Betulinic acid | −3.151 | 1.316 | 100 | 0.144 | 0.746 | No | No | No | No | No | No | No | No | No | No |
| Betulin | −4.341 | 1.331 | 100 | 0.127 | −0.29 | No | No | No | No | No | No | No | No | No | No |
| 3b Hydroxycinnamolide | −2.295 | 1.211 | 85.275 | 0.433 | −0.004 | No | No | No | No | No | Yes | No | No | No | No |
| Trametenolic acid | −3.329 | 1.203 | 100 | 0.124 | 0.735 | No | No | No | No | No | No | No | No | No | Yes |
| Spiroinonotsuoxodiol | −4.248 | 1.358 | 62.479 | 0.101 | 0.575 | No | No | No | No | No | No | No | No | No | No |
| Oleanolic acid | −3.02 | 1.252 | 53.696 | 0.151 | 0.747 | No | No | No | No | No | No | No | No | No | Yes |
| Lanosterol | −4.795 | 1.273 | 100 | 0.012 | 1.176 | No | No | No | No | No | No | No | No | Yes | No |
| Inotodiol | −4.253 | 1.416 | 100 | 0.068 | −0.291 | No | No | No | No | No | No | No | No | No | No |
| Inonotusol G | −5.974 | 1.373 | 94.283 | 0 | −0.196 | No | No | No | No | No | No | No | No | No | No |
| Inonotusol F | −4.511 | 1.418 | 100 | 0.003 | 0.678 | No | No | No | No | No | No | No | No | No | No |
| Inonotusol E | −3.74 | 0.376 | 63.728 | 0.25 | −0.165 | No | No | No | No | No | No | No | No | No | Yes |
| Inonotusol D | −3.799 | 0.687 | 62.548 | 0.149 | −0.198 | No | No | No | No | No | No | No | No | No | Yes |
| Inonotusol C | −3.799 | 0.687 | 62.548 | 0.149 | −0.198 | No | No | No | No | No | No | No | No | No | Yes |
| Inonotusol B | −3.957 | 0.631 | 64.612 | 0.308 | −0.377 | No | No | No | No | No | No | No | No | No | No |
| Inonotusol A | −3.957 | 0.631 | 64.612 | 0.308 | −0.377 | No | No | No | No | No | No | No | No | No | No |
| Inonotusic acid | −5.861 | 1.755 | 96.964 | 0 | 0.054 | Yes | Yes | No | No | No | No | No | No | No | No |
| Inonotusane C | −4.597 | 1.251 | 100 | 0.026 | −0.213 | No | No | No | No | No | No | No | No | No | No |
| Inonotusane B | −4.251 | 1.2 | 49.745 | 0.094 | 0.569 | No | No | No | No | No | No | No | No | No | No |
| Inonotsutriol E | −4.32 | 1.373 | 100 | 0.095 | −0.275 | No | No | No | No | No | No | No | No | No | No |